Clinico-pathologic disparities of breast cancer in Hispanic/Latina women.
Clinico-pathologic disparities of breast cancer in Hispanic/Latina women. Breast Dis. 2018 Jan 23;: Authors: Nahleh Z, Botrus G, Dwivedi A, Badri N, Otoukesh S, Diab N, Biswas S, Jennings M, Elzamly S Abstract BACKGROUND: Breast cancer is the leading cause of cancer death in Hispanic/Latina women nationwide. Limited cancer research has been conducted in this population. El Paso, Texas is a large border city with a population of around 900,000, of which 85% are Latinos and would provide a suitable setting for this study. The aim of this study is to evaluate ethnic differences and cancer characteristics in Hispanic/latina women with breast cancer. METHODS: After IRB approval, we retrospectively analyzed the variables of patients with breast cancer treated consecutively at a large tertiary medical center in El Paso, TX between 2005-2015. Descriptive statistics, bivariate, and multivariable analyses were conducted. RESULTS: 1,252 patients were identified. Mean age at diagnosis was 57 years. 1074 were Hispanics/Latinas (86%). When comparing Hispanics versus non-Hispanics, 31% of Hispanics compared to 24% Non-Hispanics were diagnosed at age
ConclusionsAmong breast cancer patients, nearly one-third exhibit clinical-pathological stage discordance. This high likelihood of discordance is important to consider for counseling and treatment planning.
yong-Huey Lai Endometrial cancer incidence rates are growing, especially in countries with rapid socioeconomic transitions. Despite recent advances in chemotherapy, hormone therapy, and targeted therapy, advanced/recurrent disease remains a clinical challenge. Palbociclib—a selective inhibitor of cyclin-dependent kinases (CDK) 4/6—has therapeutic potential against estrogen receptor (ER)-positive and HER2-negative breast cancer. However, the question as to whether it can be clinically useful in endometrial cancer remains open. Here, we show that combined treatment with palbociclib and megesterol acet...
A trial presented at ASCO 2019 found HER2 heterogenity can impact response rates to some treatments in HER2-positive breast cancer patients.
Oncogene, Published online: 19 July 2019; doi:10.1038/s41388-019-0893-4FABP7 is a key metabolic regulator in HER2+ breast cancer brain metastasis
CONCLUSION: Residual nodal disease after NAC analysed by LNRC or LNR = 0.25 cut-off value, is prognostic and can discriminate between favourable and unfavourable outcomes for TNBC and Her2+ breast cancers.
Condition: HER2-positive Early Breast Cancer Interventions: Drug: Pertuzumab IV; Drug: Trastuzumab IV; Drug: FDC of Pertuzumab and Trastuzumab SC; Drug: Doxorubicin; Drug: Cyclophosphamide; Drug: Docetaxel; Procedure: Surgery; Radiation: Post-Operative Radiotherapy; Drug: Hormone Therapy Sponsor: Hoffmann-La Roche Not yet recruiting
Publication date: 16 July 2019Source: Cell Reports, Volume 28, Issue 3Author(s): Pavel Bouchal, Olga T. Schubert, Jakub Faktor, Lenka Capkova, Hana Imrichova, Karolina Zoufalova, Vendula Paralova, Roman Hrstka, Yansheng Liu, Holger Alexander Ebhardt, Eva Budinska, Rudolf Nenutil, Ruedi AebersoldSummaryAccurate classification of breast tumors is vital for patient management decisions and enables more precise cancer treatment. Here, we present a quantitative proteotyping approach based on sequential windowed acquisition of all theoretical fragment ion spectra (SWATH) mass spectrometry and establish key proteins for breast tu...
HER2 (human epidermal growth factor receptor 2) is a protein that is associated with some particularly aggressive forms of breast cancer. The presence of high concentrations of this protein seems to lead to the growth of tumors, so inactivating HER2 ...
CONCLUSIONS: Adjuvant trastuzumab has substantially improved the survival of patients with HER2+ eBC, contributing over 41,000 LYG to Spanish society (over 36,000 DFLYG) in a cost-effective manner. However, the sum of LYG with trastuzumab is still far from the LY estimated for the general population, supporting the need of further advances in HER2+ eBC. PMID: 31303965 [PubMed]